Verona (VRNA) Talks Up The Long View Following Phase II Setback
Verona Pharma (NASDAQ:VRNA) highlighted a surprising benefit from a lower dose (1.5mg) in its phase II trial of RPL554, an [...]
Karyopharm’s Cancer Drug Achieves Impressive Results
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reported impressive results on December 1, 2018 for its lymphoma drug candidate Selinexor, noting patients who experienced [...]
SanaCurrents BioTech Research Service Inaugural Reports on EIDX and GLMD
Last week, Galmed Pharmaceuticals (NASDAQ:GLMD) shares climbed as high as $9.90 per share this week, up approximately 7% on the [...]
Update on Eidos Therapeutics after Positive Phase II Results
Eidos Therapeutics, Inc. (NASDAQ:EIDX) shares are up as much as 17% today after the company reported positive phase II results [...]
Galmed (GLMD) – November Catalyst: Aramchol
November Catalyst: Aramchol SanaCurrents forecasts an advantageous probability Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) will post positive results in an abstract report focused on [...]
Eidos Therapeutics (EIDX) – 4Q Catalyst: AG10 phase II data
4Q Catalyst: AG10 phase II data Based on its analytics score, SanaCurrents gives a superior sentiment rating that Eidos Therapeutics, [...]
FDA Creating New Investment Opportunities in BioTech Stocks
Because FDA marketing clearance to sell a drug or device in the US remains the brass ring for medical manufacturers [...]
SanaCurrents Introduction – Turn to the Biotech Experts to Maximize Your Returns
Introducing SanaCurrents Introducing SanaCurrents, a research service for the serious and sophisticated biotech investor. Founder of SanaCurrents, Bill Langbein, finally [...]